Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Cognitive Function in a Randomized Trial of EvolocumabThe New England journal of medicine, 2017-08, Vol.377 (7), p.633-643 [Peer Reviewed Journal]Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;info:eu-repo/semantics/openAccess ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1701131 ;PMID: 28813214Full text available |
|
2 |
Material Type: Article
|
Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial HypercholesterolemiaCirculation (New York, N.Y.), 2013-11, Vol.128 (19), p.2113-2120 [Peer Reviewed Journal]2013 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;2014 INIST-CNRS ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.113.004678 ;PMID: 24014831 ;CODEN: CIRCAZFull text available |
|
3 |
Material Type: Article
|
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trialThe Lancet (British edition), 2015-01, Vol.385 (9965), p.341-350 [Peer Reviewed Journal]Elsevier Ltd ;2015 Elsevier Ltd ;Copyright © 2015 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jan 24, 2015 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(14)61374-X ;PMID: 25282520 ;CODEN: LANCAOFull text available |
|
4 |
Material Type: Article
|
A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular RiskThe American journal of cardiology, 2016, Vol.117 (1), p.40-47 [Peer Reviewed Journal]The Authors ;2016 The Authors ;Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Jan 1, 2016 ;ISSN: 0002-9149 ;EISSN: 1879-1913 ;DOI: 10.1016/j.amjcard.2015.10.021 ;PMID: 26547291 ;CODEN: AJCDAGFull text available |
|
5 |
Material Type: Article
|
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular DiseaseThe New England journal of medicine, 2022-11, Vol.387 (20), p.1855-1864 [Peer Reviewed Journal]Copyright © 2022 Massachusetts Medical Society. All rights reserved. ;Copyright © 2022 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2211023 ;PMID: 36342163Full text available |
|
6 |
Material Type: Article
|
Inflammatory and Cholesterol Risk in the FOURIER TrialCirculation (New York, N.Y.), 2018-07, Vol.138 (2), p.131-140 [Peer Reviewed Journal]2018 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;2018 American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.118.034032 ;PMID: 29530884Full text available |
|
7 |
Material Type: Article
|
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]Journal of lipid research, 2016-06, Vol.57 (6), p.1086-1096 [Peer Reviewed Journal]2016 © 2016 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology. ;Copyright © 2016 by the American Society for Biochemistry and Molecular Biology, Inc. ;Copyright © 2016 by the American Society for Biochemistry and Molecular Biology, Inc. 2016 ;ISSN: 0022-2275 ;EISSN: 1539-7262 ;DOI: 10.1194/jlr.P065334 ;PMID: 27102113Full text available |
|
8 |
Material Type: Article
|
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trialThe American heart journal, 2016-03, Vol.173, p.94-101 [Peer Reviewed Journal]Mosby, Inc. ;2015 Elsevier Inc. ;Copyright © 2015 Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Mar 1, 2016 ;ISSN: 0002-8703 ;EISSN: 1097-6744 ;DOI: 10.1016/j.ahj.2015.11.015 ;PMID: 26920601Full text available |
|
9 |
Material Type: Article
|
Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular Risk: Primary Results From the Phase 2 YUKAWA StudyCirculation Journal, 2014, Vol.78(5), pp.1073-1082 [Peer Reviewed Journal]2014 THE JAPANESE CIRCULATION SOCIETY ;ISSN: 1346-9843 ;EISSN: 1347-4820 ;DOI: 10.1253/circj.CJ-14-0130 ;PMID: 24662398Full text available |
|
10 |
Material Type: Article
|
Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart FailureJournal of the American Heart Association, 2020-08, Vol.9 (16), p.e015042-e015042 [Peer Reviewed Journal]2020 The Authors, Amgen Inc, and Humana Inc. Published on behalf of the American Heart Association, Inc., by Wiley. ;ISSN: 2047-9980 ;EISSN: 2047-9980 ;DOI: 10.1161/jaha.119.015042 ;PMID: 32805181Full text available |
|
11 |
Material Type: Article
|
Apoptosis in neural development and diseaseAnnual review of neuroscience, 2000-01, Vol.23 (1), p.73-87 [Peer Reviewed Journal]2000 INIST-CNRS ;Copyright Annual Reviews, Inc. 2000 ;ISSN: 0147-006X ;EISSN: 1545-4126 ;DOI: 10.1146/annurev.neuro.23.1.73 ;PMID: 10845059 ;CODEN: ARNSD5Full text available |
|
12 |
Material Type: Article
|
Apaf-1 Deficiency and Neural Tube Closure Defects are Found in fog MiceProceedings of the National Academy of Sciences - PNAS, 2001-08, Vol.98 (17), p.9683-9687 [Peer Reviewed Journal]Copyright 1993-2001 National Academy of Sciences of the United States of America ;Copyright National Academy of Sciences Aug 14, 2001 ;Copyright © 2001, The National Academy of Sciences 2001 ;ISSN: 0027-8424 ;EISSN: 1091-6490 ;DOI: 10.1073/pnas.171283198 ;PMID: 11504943Full text available |
|
13 |
Material Type: Patent
|
오메캄티브 메카빌을 투여하여 심부전을 치료하는 방법Digital Resources/Online E-Resources |
|
14 |
Material Type: Patent
|
Methods of treating heart failure by administering omecamtiv mecarbilDigital Resources/Online E-Resources |
|
15 |
Material Type: Article
|
CARDIOVASCULAR BENEFIT OF EVOLOCUMAB IN 27,564 PATIENTS WITH AND WITHOUT AUTOIMMUNE OR INFLAMMATORY DISEASES: AN ANALYSIS OF THE FOURIER TRIALJournal of the American College of Cardiology, 2024-04, Vol.83 (13), p.1682-1682 [Peer Reviewed Journal]2024 American College of Cardiology Foundation ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/S0735-1097(24)03672-6Full text available |
|
16 |
Material Type: Article
|
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIERCirculation (New York, N.Y.), 2018-08, Vol.138 (8), p.756-766 [Peer Reviewed Journal]2018 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.118.034309 ;PMID: 29626068Full text available |
|
17 |
Material Type: Article
|
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable AtherosclerosisStroke (1970), 2020-05, Vol.51 (5), p.1546-1554 [Peer Reviewed Journal]2020 American Heart Association, Inc. ;ISSN: 0039-2499 ;EISSN: 1524-4628 ;DOI: 10.1161/STROKEAHA.119.027759 ;PMID: 32312223Full text available |
|
18 |
Material Type: Patent
|
METHODS OF TREATING HEART FAILURE WITH CARDIAC SARCOMERE ACTIVATORSDigital Resources/Online E-Resources |
|
19 |
Material Type: Article
|
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trialThe Lancet (British edition), 2016-12, Vol.388 (10062), p.2895-2903 [Peer Reviewed Journal]Elsevier Ltd ;2016 Elsevier Ltd ;Copyright © 2016 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Dec 10, 2016 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(16)32049-9 ;PMID: 27914656 ;CODEN: LANCAOFull text available |
|
20 |
Material Type: Article
|
THE EFFECT OF THE CARDIAC MYOSIN ACTIVATOR, MECAMTIV MECARBIL, ON RIGHT VENTRICULAR STRUCTURE AND FUNCTION IN CHRONIC SYSTOLIC HEART FAILURE (COSMIC-HF)Journal of the American College of Cardiology, 2020-03, Vol.75 (11), p.667-667 [Peer Reviewed Journal]2020 American College of Cardiology Foundation ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/S0735-1097(20)31294-8Full text available |